Atypical Antipsychotic Market Snapshot: Making Way For Three New Drugs
Executive Summary
Three newly-approved drugs - Schering Plough's Saphris, Johnson & Johnson's Invega Sustenna and Vanda's Fanapt - are poised to enter the atypical antipsychotic space despite the crowd of approved products and the specter of market genericization
You may also be interested in...
J&J Pushes New Treatment Paradigm for Invega Sustenna
Johnson & Johnson is looking at innovative ways to build the value of its just-approved, monthly injectable schizophrenia drug Invega Sustenna, including continuing ongoing outcomes studies and creating appropriate partnerships with payers and others, as part of a broader plan for a "new treatment paradigm" in the treatment of schizophrenia
J&J Pushes New Treatment Paradigm for Invega Sustenna
Johnson & Johnson is looking at innovative ways to build the value of its just-approved, monthly injectable schizophrenia drug Invega Sustenna, including continuing ongoing outcomes studies and creating appropriate partnerships with payers and others, as part of a broader plan for a "new treatment paradigm" in the treatment of schizophrenia
Novartis Deal Sealed, Vanda Plays Up Injectable Potential
Vanda turns near-rags to riches selling Fanapt rights back to the originator, a rare feat for a drug in-licensed from Big Pharma.